Clinical trials: Cutaneous Melanoma, Stage II
Melanoma (Skin)
O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma
Phase II trial to study the effectiveness of O6-benzylguanine and carmustine in treating patients who have unresectable locally recurrent or metastatic melanoma.
- Trial name
- NCT00005961
- Testing
- O6-benzylguanine, carmustine
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from a person's white blood cells and a donor's tumor cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00107159
- Testing
- autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma Stage III or IV
Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients
Dendritic cells (DCs)are the most potent antigen-presenting cells of the immune system, as such they are able to direct the immune system specifically against cancer cells.
- Trial name
- NCT00243529
- Testing
- autologous dendritic cell vaccine
- Where
- Netherlands
- Volunteers
- 64 people
- Sponsor
- Radboud University Medical Center
Stage IV Uveal Melanoma
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
The purpose of this study is to determine whether radiation provided locally to the liver tumor vasculature environment will demonstrate a response of tumor decline. This radiation may cause the tumor cells to die.
- Trial name
- NCT01473004
- Testing
- Sir-Spheres®
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Thomas Jefferson University
Melanoma (Skin)
Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00003568
- Testing
- aldesleukin, gp100 antigen, incomplete Freund's adjuvant
- Where
- 9 sites in United States
- Sponsor
- University of Illinois Chicago
Stage IB Melanoma, Stage IIA Melanoma
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
This randomized phase III trial studies sargramostim before sentinel lymph node biopsy to see how well it works compared to hypertonic saline before sentinel lymph node biopsy in treating patients with melanoma.
- Conditions
- Stage IB Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
- Trial name
- NCT01826864
- Testing
- sargramostim, sentinel lymph node biopsy, laboratory biomarker analysis
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma of Skin, Acral Melanoma
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as postoperative adjuvant therapy in patients with clinical…
- Conditions
- Melanoma of Skin, Acral Melanoma, Stage II Melanoma
- Trial name
- FUMS-EDJS2024 (NCT06965231)
- Testing
- Toripalimab combined with Endostar
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Melanoma
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma.
- Trial name
- NCT01067066
- Testing
- TPI 287, Temodar (Temozolomide)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa
RATIONALE: Interferon alfa may interfere with the growth of tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining interferon alfa plus radiation therapy may kill more tumor cells.
- Trial name
- NCT00005615
- Testing
- Interferon alfa, Radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Recurrent Melanoma, Stage IV Melanoma
Viral Therapy in Treating Patients With Metastatic Melanoma
This phase II trial is studying the side effects and how well viral therapy works in treating patients with metastatic melanoma. Viral therapy may be able to kill tumor cells without damaging normal cells.
- Trial name
- NCT00651157
- Testing
- wild-type reovirus
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Stage III Malignant Melanoma of Skin AJCC V6, Stage IV Malignant Melanoma of Skin
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
Implementing this protocol has its ethical justification in that patients with metastatic melanoma, once tumor invasion has reached beyond the lymph node barrier, cannot possibly be treated satisfactorily with traditional surgery…
- Trial name
- NCT06152367
- Testing
- TAPCells vaccine
- Where
- Chile
- Volunteers
- 90 people
- Sponsor
- University of Chile
Metastatic Melanoma
A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)
The main objective of this study is to evaluate the clinical and biologic toxicity of cell therapy by adoptive transfer of TIL in combination with intra-tumoral injections of Ad-INFg.
- Trial name
- NCT01082887
- Testing
- TIL-Ad-INFg
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Nantes University Hospital
Extraocular Extension Melanoma, Metastatic Intraocular Melanoma
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma
- Trial name
- NCT01533948
- Testing
- axitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roswell Park Cancer Institute
Melanoma (Skin)
Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma
Phase II trial to study the effectiveness of combining thalidomide and SU5416 in treating patients who have metastatic melanoma.
- Trial name
- NCT00017316
- Testing
- semaxanib, thalidomide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Recurrent Melanoma, Stage IV Melanoma
Tipifarnib in Treating Patients With Metastatic Malignant Melanoma
This phase II trial is studying how well tipifarnib works in treating patients with metastatic malignant melanoma. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00060125
- Testing
- tipifarnib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin), Sarcoma
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing chemotherapy to the tumor area only may kill more tumor cells and cause less damage to healthy…
- Trial name
- NCT00004250
- Testing
- dactinomycin, isolated limb perfusion, melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with stage IV melanoma.
- Conditions
- Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma, Nodular Malignant Melanoma, Recurrent Melanoma
- Trial name
- NCT01120275
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
- Where
- 178 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer, Stage IV Solid Tumor Cancer
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
The PEARL Pilot is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
- Conditions
- Advanced Cancer, Stage IV Solid Tumor Cancer, Stage IV Sarcoma of Bone, Stage IV Lymphoma
- Trial name
- NCT06416085
- Testing
- Psilocybin
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Melanoma (Skin)
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004184
- Testing
- monoclonal antibody 4B5 anti-idiotype vaccine, sargramostim, alum adjuvant
- Volunteers
- 50 people
- Sponsor
- University of Alabama at Birmingham